EXAGEN INC

Company Overview

Exagen Inc. is a Healthcare company in the Diagnostics & Research industry that develops and commercializes autoimmune testing products under its AVISE® brand. Its core business is highly concentrated in the AVISE® CTD panel, which is used to help diagnose, prognose, and monitor complex rheumatic and autoimmune diseases such as lupus and rheumatoid arthritis. The company operates a specialty lab model from its CLIA-certified facility in California and sells primarily to U.S. rheumatologists. Recent filings show strong revenue growth, driven by higher test volume, improved pricing, and early adoption of newer biomarkers.

Executive Compensation Practices

For a diagnostics company like Exagen, executive compensation is likely tied to a mix of revenue growth, test volume, average selling price (ASP), gross margin expansion, and cash burn reduction, since these are the clearest operational drivers in the filings. Because management is in a turnaround and commercialization phase, incentive plans may also emphasize commercial execution metrics such as physician adoption, reimbursement progress, payer coverage wins, and successful product launches rather than profitability alone. The company’s rising SG&A and R&D costs suggest compensation may also reward scaling the sales force and advancing the biomarker pipeline while maintaining disciplined spending. In a Healthcare / Diagnostics & Research business, executives often receive equity-heavy pay to align them with longer-term reimbursement, product adoption, and pipeline milestones.

Insider Trading Considerations

Insider trading patterns for Exagen should be interpreted in the context of a company whose valuation is highly sensitive to reimbursement decisions, test adoption trends, and margin improvement. Because revenue is concentrated in AVISE® CTD and depend heavily on payor coverage and collection assumptions, insiders may trade around periods when reimbursement updates, pricing changes, or volume trends become clearer. Positive clinical or commercial milestones—such as new biomarker launches, payer coverage expansion, or evidence of sustained ASP improvement—could create bullish insider sentiment, while denials, policy setbacks, or unexpected cash burn could increase selling pressure or caution. As a regulated healthcare diagnostics company, insiders may also face tighter blackout windows around earnings and material updates, especially given the company’s use of estimates and sensitive revenue-recognition judgments.